New lung cancer indication for Tarceva

In the SATURN trial in 889 patients with locally advanced or metastatic NSCLC whose disease had not progressed after 4 cycles of platinum-based doublet chemotherapy, mean progression-free survival was 22.4 weeks in the erlotinib group compared with 1
In the SATURN trial in 889 patients with locally advanced or metastatic NSCLC whose disease had not progressed after 4 cycles of platinum-based doublet chemotherapy, mean progression-free survival was 22.4 weeks in the erlotinib group compared with 1

The licence for Tarceva (erlotinib) has been extended to include maintenance therapy in non-small cell lung cancer (NSCLC). It can now be used as monotherapy in patients with locally advanced or metastatic NSCLC with stable disease after four cycles of standard platinum-based first-line chemotherapy.

Tarceva is also licensed for the treatment of locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen, and in combination with gemcitabine for metastatic pancreatic cancer.

View Tarceva drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more